MetaCap

CG Oncology Inc. (CGON)

NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

79.47-2.43 (-2.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CGON stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.76
52-week range
37.01 – 93.95
Day range
79.23 – 83.12
Volume / Avg
1.67M / 1.24M
Beta
—

52-week range

$37.01$93.95

CGON stock today

CG Oncology (CGON) closed at $79.47 on Nov 20, down 2.97% (-$2.43), versus the S&P 500's 3.70% decline. Shares are 15.4% below their 52-week high of $93.95, set on Nov 16, 2026 and 114.7% above the 52-week low of $37.01, in the middle of the past year's range. CGON is up 91.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 87.3%.

CG Oncology has posted a net loss over the last twelve months (EPS of -$2.76), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About CG Oncology

Company profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Arthur Kuan
Headquarters
Dallas, TX
Employees
142
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, CG Oncology generated $4.0 million in revenue, up 254.7% from fiscal 2024, its 2nd consecutive year of revenue growth. CG Oncology reported a net loss of $161.0 million, compared with a loss of $88.0 million a year earlier. Operating margin was -4722.1%.

CG Oncology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$4.04M$1.14M$204.00K
Growth+254.70%+458.33%—
Net income$-161.00M$-88.04M$-48.61M
EPS (diluted)$-2.08$-1.41$-15.65

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$109.69+38.03%

  • Strong buy 3
  • Buy 10
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $87.00High $150.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.64 vs $-0.86
Surprise
+25.58%

CGON news

All CGON news

CG Oncology peers

Health Care sector
CGON peer companies
CompanyPrice% ChgMarket capCompare
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs CGON
IMVTImmunovant Inc.31.77-2.31%$6.57Bvs CGON
IBRXImmunityBio Inc.6.02-8.37%$6.40Bvs CGON
KODKodiak Sciences Inc97.17-0.75%$6.35Bvs CGON
SRRKScholar Rock Holding Corporation48.13-4.45%$5.87Bvs CGON
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs CGON
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs CGON
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs CGON

Indexes, lists and sector

CG Oncology stock FAQ

What is CG Oncology's stock price today?

CGON last traded at $79.47 as of Nov 20, 4:00 PM EST, down 2.97% on the day. Prices are delayed at least 15 minutes.

Who is CG Oncology's CEO?

Mr. Arthur Kuan is the chief executive officer of CG Oncology Inc., which has about 142 employees.

What is the CGON 52-week high?

The 52-week high for CGON is $93.95 and the 52-week low is $37.01. The stock is currently 15.4% below its high.

Compare CGON